In the intensive care unit, we often reach for blood tests as our window into the body’s response to critical illness. But what happens when the very tests we order begin to chip away at the patient’s ability to recover? Iatrogenic anemia—anemia caused or worsened by medical intervention, particularly diagnostic blood draws—is a well-documented but underappreciated complication of hospitalization, especially in critically ill patients. And while transfusion can be life-saving, it comes with its own risks, costs, and carbon footprint. Preventing the anemia in the first place is often safer, cheaper, and more sustainable. The Scope of the Problem In one large observational cohort from a U.S. academic medical center, critically ill patients underwent a median of 41 laboratory draws per hospitalization, with a median blood loss of 232 mL per patient—about half a unit of red cells (Luke et al., 2023). Daily losses in some ICUs approached 29 mL, and discard volumes—blood drawn but not analyzed—accounted for more than 10% of this loss. The consequences are not benign. Hemoglobin levels decline in proportion to phlebotomy intensity, and each 100 mL of blood drawn was associated with a 1.15x increase in red cell transfusion use. Patients with the highest cumulative blood loss had the lowest nadir hemoglobin values, longest hospital stays, and highest transfusion requirements. In neonatal ICU patients, the burden is even more staggering: up to 90% of circulating blood volume can be removed in the first two weeks of life alone (Widness et al., 1996). Strategies to Reduce Iatrogenic Blood Loss Patient Blood Management (PBM) strategies focus on three pillars: Optimizing anemia management Reducing iatrogenic blood loss Enhancing tolerance of anemia This post focuses on the second pillar—particularly blood-sparing techniques like: Small volume tubes (SVT) Closed blood sampling devices (CBSD) Point-of-care testing (POCT) Educational and policy interventions Bundled strategies combining the above Systematic reviews consistently show that SVT and CBSD both reduce blood draw volumes, but the data are mixed regarding their ability to reduce transfusion rates or prevent hemoglobin decline (Whitehead et al., 2019; François et al., 2022; Keogh et al., 2023). The most substantial blood conservation has been achieved through CBSD, which returns unused blood to the circuit, eliminating discard volume altogether. Yet one tool in particular—point-of-care testing—offers an especially compelling combination of blood conservation, clinical responsiveness, and workflow efficiency. Point-of-Care Testing: High Impact, Low Volume Unlike conventional lab draws, POCT uses minimal sample volumes—often 100–250 µL—and delivers results in minutes. While often framed as a convenience tool, POCT may play a crucial role in blood conservation strategies. In a NICU cohort, Madan et al. found that switching to a bedside POCT analyzer for blood gas and electrolyte testing resulted in a 46% reduction in transfusions and a 43% reduction in total transfused volume among extremely low birth weight infants (Madan et al., 2005). Notably, the frequency of testing remained unchanged, suggesting the volume savings alone made the difference. Mahieu et al. similarly observed a 48% reduction in transfusion volume among very low birth weight infants following the introduction of a POCT analyzer (Mahieu et al., 2017). Blood loss per test was significantly reduced, and the intervention was cost-saving for the national health system. In an adult ICU cohort, Salem et al. demonstrated that POCT instruments provided accurate analyte results while using only 250 µL of blood. They highlighted the role of microchemistry technology in reducing blood loss, particularly in high-acuity settings like emergency departments and operating rooms. Despite differences in study populations and methodologies, these studies converge on one key finding: POCT can reduce diagnostic blood loss and transfusion needs without compromising care. The Benefits and Risks of POCT The benefits of POCT in critical care go beyond sample volume: Faster turnaround times allow more rapid clinical decisions. Less blood drawn per test reduces the risk of phlebotomy-induced anemia. Testing at the bedside minimizes pre-analytical errors (like transport delays or sample degradation). Capillary sampling options may eliminate the need for venipuncture entirely in some cases. But there are trade-offs to consider: Differences between capillary and venous/arterial blood can affect interpretability, especially for certain analytes. Some devices have lower throughput and limited test menus compared to central labs. Repeat testing or confirmation may still be necessary, particularly for critical or unexpected values. Integration into clinical workflows—from staff training to EMR connectivity—requires planning. POCT is not a replacement for central labs, but a complementary tool. When deployed strategically—especially in high-volume testing environments like the ICU—it offers a meaningful reduction in both blood volume drawn and time to actionable data. Implementing Change: More Than Just Tubes While no single intervention prevents iatrogenic anemia on its own, the evidence supports integrating POCT and other blood-sparing strategies into routine practice, especially for ICU patients with prolonged stays or at high risk of transfusion. Barriers remain—cost, workflow adaptation, and concerns about test redundancy or accuracy—but as the data accumulate, so does the imperative to act. This is not just a patient safety issue; it’s also a sustainability issue. As one review noted, each routine lab test generates measurable carbon emissions, with full blood counts producing the equivalent of 770 meters of car travel (McAlister et al., 2022). Conclusion Iatrogenic anemia is not an inevitable side effect of ICU care—it’s a modifiable risk. By leveraging technologies like POCT, rethinking default test ordering, and aligning with PBM principles, we can reduce unnecessary blood loss, avoid transfusions, and improve outcomes for some of our sickest patients. Because sometimes, doing less really is doing more.

Introduction: When most people—doctors included—think of transfusion medicine, they picture someone approving blood products from a distance. Maybe they imagine a pathologist tucked away in the lab, rubber-stamping PRBC requests. But the reality is far more complex. Transfusion medicine physicians are clinical consultants, working at the intersection of hematology, immunology, and patient blood management. Our value lies not just in saying “yes” or “no” to transfusion, but in guiding clinicians through diagnostic uncertainty, navigating difficult cases, and improving outcomes across a wide variety of specialties. 1. A Consultative Specialty Hidden in Plain Sight Transfusion medicine isn’t a field most people choose—it’s one they discover. And when they do, they realize how central it is to patient care. TM physicians are consulted for cases that don’t fit cleanly into another box: A patient with a positive DAT and unclear hemolysis A stem cell transplant patient with febrile reactions to every unit A Jehovah’s Witness patient needing complex surgery A trauma patient with coagulopathy and no clear path forward We're brought in not just to approve blood, but to ask: Is this the right product? At the right dose? At the right time? 2. Diagnostic Expertise in Complex Cases TM consults often involve layered diagnostic reasoning. Is this hemolysis immune or non-immune? Is this thrombocytopenia ITP or drug-induced? Are we dealing with a warm autoantibody or an alloantibody in disguise? Transfusion medicine physicians integrate lab data, clinical context, and patient-specific nuances to provide recommendations that change management—not just transfusion plans, but workups, drug choices, and timelines. 3. Interdisciplinary Communication We speak many clinical dialects—cardiology, surgery, hematology, anesthesia—and translate lab findings into actionable recommendations. TM physicians regularly facilitate multidisciplinary conversations: Should we give platelets before this LP in a thrombocytopenic patient with MDS? Can we safely delay transfusion until after antibody identification? Is there a non-transfusion alternative that fits this patient’s values or goals of care? We're often the glue in communication between lab and floor, between policy and practice. 4. Blood as a Finite Resource—and a Clinical Tool Transfusion is not a benign act. Every unit carries risk: alloimmunization, TRALI, volume overload, and more. TM physicians help balance benefit and harm, especially in gray-zone cases. We advise not just on when to transfuse, but when not to: Recommending alternatives to transfusion in chronic anemia Guiding single-unit transfusion strategies Implementing PBM protocols in the ICU or OR 5. Beyond the Bedside: Policy, Quality, and Stewardship We’re also system stewards. TM physicians lead hospital transfusion committees, write massive transfusion protocols, track utilization metrics, and intervene when transfusion practices drift. Our consultative lens applies at the system level as well as the bedside. Conclusion: Transfusion medicine is not just technical—it’s clinical. Every blood product order is a clinical decision, and TM physicians are consultants in the truest sense: integrators of data, translators between teams, and advocates for safe, appropriate, patient-centered care. So next time you call the blood bank, remember: you’re not just calling to release a unit. You’re calling a consultant.

In just a few short weeks, I’ll finish fellowship. It’s not my first goodbye — far from it. But it’s the first one that might be my last. The last rotation. The last ID badge with an expiration date. The last institutional email address that will vanish the moment I step out the door. Then again, maybe not. I’ve done this enough times to know better. For the past six years, I’ve been in training. Which means I’ve also been leaving — constantly. Four major moves, three different states, countless rotations, and more logins and locker combinations than I could ever remember. Every space was temporary. Every system required re-onboarding. Every community came with an asterisk: not yours, not forever. That’s just how training works. We are a profession built on transience. You adapt quickly. You learn which bathrooms are cleanest, how to label your samples so they don’t get lost, which attendings want you to speak up and which don’t. You settle in fast, because you won’t be there long. And eventually, you learn to stop unpacking fully — not just your suitcase, but yourself. Some things I expect to miss — the bespoke patient care at the NIH. The way consults end with research questions, not billing concerns. The handful of people who made the day easier, who made you smarter without making you feel small. Other things I won’t miss at all. That’s part of it, too. But the grief that sticks with me isn’t always about the work. It’s the friendships that faded after the group chat went quiet. The cities I never really got to know. The long nights trying to decide what to throw out, because it wouldn’t fit in the moving truck. The Dresden doll from my grandmother — broken in one move. The journals I kept when I was 15 — lost in another. The people I was in those places, with those objects, doing that work — gone, or at least out of reach. I’ve spent six years learning how to leave. Sometimes gracefully, sometimes frantically, always carrying a little less than when I arrived. But for all the things I’ve lost, some things stayed. A few friendships, kept alive through effort and luck. A favorite pen. A writing ritual. The conviction that my voice matters, even in rooms that don’t expect to hear it. That’s what transition teaches you, if you pay attention: how to find meaning in borrowed space. How to build a life in 4-week blocks. How to say goodbye before it feels finished. How to carry forward what matters when most of it can’t come with you. This next move — to a faculty job, a new home, a place with no scheduled end date — is supposed to be permanent. But I’ve lived enough life in medicine to know that permanence is a story we tell ourselves to feel safe. I’ve moved too many times to believe in permanence. But I believe in showing up — even when the future is uncertain. So I’ll show up. I’ll care. I’ll build something worth keeping, even if I might have to let it go.

James is a 20-pound tabby with a big personality and, until recently, a very small urethra. A few weeks ago, he ended up in the emergency hospital with a urinary obstruction. He was stable, uncomfortable, and unimpressed. I was stressed out, sleep-deprived, and fully bracing for chaos. But the chaos never came. While James was still in the hospital, the specialty vet electronically sent detailed updates to his primary vet. When complications came up post-op, his primary vet reviewed the plan, prescribed the necessary meds, and followed through without punting anything back. Everyone seemed to know his case, take it seriously, and work together to make sure he got what he needed. It was surreal. Because somewhere between admission and discharge, I realized that my cat was getting better healthcare than I’ve ever had as a human patient. Or, honestly, even as a physician. Coordinated. Competent. Electronic. It’s hard to overstate how smoothly the logistics went during this latest hospitalization. The specialty team didn’t just say  they’d update his PCP — they did  it, electronically, before I even asked. His outpatient vet received the records in real time and acted on them. No phone tag. No “you’ll have to call them for that.” No “we don’t prescribe meds from another facility.” And it wasn’t even the first time veterinary medicine made me feel this way. Last summer, James needed a cardiac workup. He had a same-day echocardiogram, full radiologist interpretation, lab work, and a printed summary with a diagnosis and treatment plan — before we left the office . The total cost was under $1,000. That same  summer, I also needed a cardiac workup — for a new arrhythmia. It took over two months to get scheduled. I had to ask repeatedly just to find out what the test showed. And it cost nearly $10,000. Two separate systems. Two separate workups. And the only one that felt coordinated, compassionate, and efficient was the one provided to my precious fur baby. I’ve Never Been Heard Like This What I didn’t expect was how seen  I would feel throughout the process of James' hospitalization. Everyone listened. Every question was taken seriously. I wasn’t made to feel dramatic, or pushy, or irrational for advocating for my cat’s care — even when I brought up logistics, behavior changes, or subtle shifts in appetite. It hit me harder than I expected. Because I’ve spent years navigating healthcare — as a physician, as a patient, and as a caregiver. And I’ve never had this many people listen to me without needing to fight for it. Not once. Not when I brought my own symptoms to the table. Not when I managed a family member’s decline. Not when I offered clinical context as a fellow physician. It was veterinary medicine, not human medicine, that finally made me feel heard. The System Isn’t Perfect — But It Works Of course, veterinary medicine has its own barriers. Cost can be crushing. There’s no equivalent of Medicaid. There are no safety nets. But in terms of the actual delivery  of care — communication, coordination, respect — the system worked shockingly well. There was no deferral, no fragmentation, no fax-machine absurdity. There was thoughtful, consistent, and humane care. And I can’t stop thinking about it. Because if we can offer that kind of continuity and compassion to a 20-pound tabby recovering from major surgery, why is it still so hard to do the same for people? He’s Fine. I’m Grateful. And A Little Furious. James is doing great now. He had his perineal urethrostomy and bounced back without complications. His appetite is back. His fur is shiny. He’s napping aggressively in sunbeams like nothing ever happened. I, on the other hand, keep thinking about the fact that he had a smoother clinical course, a faster diagnosis, more continuity of care, and a clearer discharge plan than I’ve ever had for my own body. And I keep thinking: If my cat can have that kind of care, maybe people should too.

Extracorporeal photopheresis (ECP) is an immunomodulatory therapy increasingly used in the management of acute and chronic graft-versus-host disease (GVHD), particularly in pediatric patients for whom traditional therapies may fall short. Despite promising outcomes, pediatric ECP remains a niche practice characterized by significant variability in technique, access, safety protocols, and clinical outcomes. This post integrates insights from two comprehensive reviews to explore practical and clinical aspects of pediatric ECP, combining real-world experience with calls for standardization and research. 1. What is ECP and How Does it Work? ECP is a cellular therapy involving: Leukapheresis  to collect white blood cells (WBCs) Incubation  with 8-methoxypsoralen (8-MOP), a photosensitizer Exposure to UVA light Reinfusion  of the treated WBCs into the patient This process is thought to promote immune tolerance by shifting immune responses from inflammatory (Th1) to regulatory (Th2) profiles, inducing apoptosis of pro-inflammatory cells, and increasing regulatory T-cell populations. While the exact mechanism in GVHD remains unclear, multiple pathways including cytokine modulation, monocyte differentiation, and B-cell regulation have been implicated. 2. ECP Systems: In-Line vs. Off-Line Feature In-Line (UVAR XTS, CELLEX) Off-Line (COBE Spectra, COM.TEC, etc.) System Type Closed, automated Open, manual Leukapheresis & Irradiation Integrated Performed on separate devices Flow Type Discontinuous (XTS) / Continuous (CELLEX) Continuous preferred Extracorporeal Volume (EV) XTS: up to 480 mL, CELLEX: ~216–266 mL Variable (lowest: COM.TEC at 137 mL) Continuous flow systems yield more mononuclear cells (MNCs) and reduce EV, making them preferable for pediatric use. 3. Indications and Clinical Outcomes in Pediatrics In children, ECP is primarily used for: Steroid-refractory acute GVHD : response rates 50–100%, depending on organ involvement Chronic GVHD : ~60% response rate; enables steroid tapering However, all current data come from case series or observational studies— no randomized controlled trials (RCTs)  have included patients under 17 years. While adult RCTs suggest efficacy, extrapolation to pediatrics requires caution. 4. Technical and Clinical Challenges A. Extracorporeal Volume (EV) High EV can cause hypotension and hemodynamic instability in low-weight children. Strategies to minimize risk: Use lower-EV devices (e.g., CELLEX, COM.TEC) Prime circuit with red blood cells (RBCs) or 5% albumin Administer saline or albumin boluses pre-procedure Device EV (mL) Min. Weight Recommendations UVAR XTS 480 >40 kg (with priming) CELLEX 216–266 >30 kg (without priming) COM.TEC 137 <30 kg (with priming preferred) B. Vascular Access Central venous catheters (single- or double-lumen) are commonly used Catheter-related infections and occlusions are the most frequent complications Reported Complication Rates: Infections: 3.7–7% Occlusion: ~4% Preventive measures: urokinase/tPA, aseptic technique, dedicated central lines C. Hematologic and Metabolic Considerations ECP can cause modest drops in hematologic parameters: Hemoglobin: median drop of 1.5 g/dL Platelets: median drop of 17% Typical Pre-Procedural Lab Cutoffs: Parameter Threshold Hematocrit >24–28% Platelet count >20,000–50,000/µL WBC count >1,000/µL There is no consensus on ideal target cell yields or on correlation between infused MNC counts and clinical efficacy. 5. Scheduling and Duration of Therapy Protocols vary widely: Initial Phase:  2–3 treatments/week Maintenance:  Decrease to every 2–4 weeks based on response GVHD Monitoring:  Weekly for aGVHD, every 1–2 months for cGVHD Study Initial Schedule Tapering Kanold 3x/week for 3 weeks Gradual taper Messina 2x/week for 1 month, biweekly for 2 months Then monthly for 3+ months Foss No difference found between 1x vs 2x/week Schedules individualized There is no evidence that more intensive schedules yield better outcomes. 6. Alternative Techniques: Mini Buffy Coat ECP For children who cannot tolerate leukapheresis: Mini buffy coat method  involves collecting 100–200 mL of whole blood Buffy coat is prepared and irradiated in a closed system Red cells, plasma, and platelets are returned to the patient Clinical Results: 84% response rate in pediatric aGVHD Strong correlation between higher WBC dose/kg and response This technique may be a valuable alternative in patients <20 kg. 7. Gaps in Knowledge and Recommendations Despite widespread clinical use, pediatric ECP suffers from a lack of standardization and rigorous evidence. Key areas needing further research include: Domain Current Gaps Recommendations Patient selection No consensus on minimum weight or lab cutoffs Develop evidence-based eligibility guidelines Product evaluation No QC benchmarks or ideal cell dose/kg Define and validate efficacy markers Anticoagulation protocols Heparin vs. citrate strategies vary by center Standardize anticoagulation practices based on risk Scheduling Highly variable schedules Conduct studies comparing intensive vs. tapered regimens Vascular access Complications common Guidelines for catheter type and maintenance Alternative collection methods Mini ECP underutilized Further evaluate in RCTs or multicenter trials 8. Conclusion ECP is a safe, well-tolerated, and potentially effective treatment for pediatric GVHD, particularly in steroid-refractory cases. However, practice varies widely, and most evidence is derived from observational data. To expand safe access and improve outcomes, standardized protocols and prospective studies—especially randomized trials in pediatric populations—are urgently needed. Until then, successful ECP in children will continue to rely on experienced multidisciplinary teams, careful patient selection, and vigilant monitoring. Have experience with pediatric ECP in your institution? Let us know what’s working—and what’s not. References DeSimone RA, Schwartz J, Schneiderman J. Extracorporeal photopheresis in pediatric patients: Practical and technical considerations. J Clin Apher. 2017; 32: 543–552. https://doi.org/10.1002/jca.21534 Sniecinski, I., & Seghatchian, J. (2017). Factual reflections and recommendations on extracorporeal photopheresis in pediatrics. Transfusion and Apheresis Science , 56 (2), 118-122. https://doi.org/10.1016/j.transci.2017.03.013Get rights and content

Introduction Most blood donors walk out of the collection center with little more than a bandage and a juice box. But for a small subset, the donation experience can be complicated by physiologic reactions—ranging from mild lightheadedness to full-blown syncope. These events, often referred to as “donor reactions,” are typically benign and self-limited, but they matter. For transfusion medicine physicians and trainees, recognizing and managing these reactions is critical—not just for donor safety, but for maintaining public trust in the blood supply. This post outlines the most common donor reactions, their mechanisms, risk factors, and management strategies, with a focus on practical relevance for pathology residents and fellows rotating through transfusion medicine. What Is a Donor Reaction? A donor reaction refers to any adverse response experienced by a blood donor during or shortly after donation. While most are mild, some can be alarming or—rarely—require clinical intervention. Reactions are classified by physiologic mechanism (e.g., vasovagal, mechanical, or citrate-related) and by severity (mild, moderate, or severe). Understanding how to identify, manage, and prevent these events is essential for ensuring a safe and positive donation experience. The Most Common Reactions Vasovagal Reactions These are the most common donor reactions and are caused by increased vagal tone, leading to transient hypotension and bradycardia. Clinical features include: Lightheadedness, dizziness, visual changes Nausea Sweating, pallor Syncope—with or without convulsions , which can be brief and non-epileptic but very alarming Management: Prompt recognition of prodrome Supine positioning with legs elevated Cold compresses to face and neck Reassurance and quiet environment Monitor until symptoms resolve Syncope is more common in: First-time donors Younger donors (particularly adolescents) Female donors , likely due to a combination of physiologic and psychosocial factors Donors with low blood volume or anxiety Hematoma Formation and Bruising Occurs when blood leaks from the vein into surrounding tissue, often from a partial needle dislodgement or inadequate compression post-donation. Management: Immediate removal of needle if infiltration occurs Apply firm pressure until bleeding stops Cold compresses in the first 24 hours; warm compresses afterward Pressure dressing  for larger hematomas Documentation and follow-up if significant Citrate Reaction (Apheresis Only) Due to systemic binding of ionized calcium by citrate anticoagulant: Perioral or fingertip tingling Muscle cramping Nausea Metallic taste Rarely, severe symptoms like tetany or arrhythmias Management: Oral calcium supplementation Slowing the ACD infusion rate Intravenous calcium in rare severe cases Nausea and Vomiting May overlap with vasovagal symptoms or occur due to anxiety, dehydration, or prolonged fasting. Management: Supine positioning Fluids and rest Discreet handling and privacy for emesis events Delayed Reactions Some donors feel dizzy or fatigued hours later, especially if they resume vigorous activity too soon. Management: Education at time of donation: hydration, rest, activity restrictions Provide emergency contact if symptoms worsen Less Common but Important Reactions Nerve Irritation or Injury Direct trauma or compression of adjacent nerves (e.g., median or cutaneous nerves) may result in: Shooting or radiating pain during phlebotomy Persistent numbness, tingling, or weakness Management: Immediate needle removal if pain occurs Documentation and donor follow-up Referral to occupational health if symptoms persist Arterial Puncture Rare but potentially serious complication when an artery is inadvertently accessed instead of a vein. Signs: Rapid filling of collection bag Bright red, pulsatile blood High pressure flow into the tubing Hematoma formation at site Management: Immediate cessation of collection Remove needle and apply firm, prolonged pressure  (at least 10 minutes) Use a pressure dressing Document and advise donor to seek care for signs of compartment syndrome or neurologic deficits Who's at Risk? Certain donor profiles consistently show higher rates of adverse reactions. First-time donors  are especially vulnerable due to unfamiliarity, needle anxiety, or fear of the process. Adolescents and young adults —particularly female donors —also experience higher rates of vasovagal syncope, likely due to heightened autonomic reactivity and lower circulating blood volume. Add dehydration, low BMI, or a skipped meal, and the risk rises further. A quick pre-donation conversation can go a long way: asking about prior reactions, encouraging hydration, and recognizing nervous body language are simple, high-yield interventions for anticipating and reducing reactions. Prevention and Mitigation Strategies Donor safety starts before the needle is even placed. Encourage donors to hydrate and eat beforehand, and offer a salty snack to expand plasma volume. For apheresis donors, provide oral calcium to prevent citrate-related symptoms. During collection, reclined positioning and attentive monitoring are key. Early signs of a vasovagal reaction—yawning, pallor, sweating—should prompt immediate action: stop the draw, recline the donor, apply cold compresses, and offer reassurance. Most syncopal episodes resolve quickly with these measures. Post-donation, ensure donors rest briefly, hydrate, and receive clear instructions about avoiding strenuous activity. Empathetic handling of reactions reinforces trust and can turn even a rocky first donation into a repeat experience. Why It Matters Donor reactions are not just operational issues—they are clinical events that influence public trust in the blood supply. Even minor reactions can deter repeat donation. As pathology residents and fellows, you may be called on to evaluate donor events, participate in root cause analysis, or improve donor screening and safety protocols. Your ability to understand and address these events directly impacts donor retention and transfusion system integrity. Final Thoughts Common donor reactions are rarely dangerous but deserve careful attention. Early recognition, effective management, and thorough documentation help keep donors safe and confident in the system. From a minor faint to a hematoma to a rare arterial puncture, every reaction is an opportunity to improve our systems—and to advocate for those whose generosity makes transfusion possible.

Warm autoantibodies (WAAs) are one of the most conceptually strange and serologically compelling phenomena in transfusion medicine. They break all the rules. And a recent case reminded me just how much art is involved in managing them—even when the science is sound. The patient was an older adult with newly identified anemia. The indirect antiglobulin test (IAT) was strongly panreactive at 4+. The direct antiglobulin test (DAT) lit up too—4+ with polyspecific antihuman globulin and anti-IgG, but negative with anti-C3. There were signs of hemolysis: elevated LDH and indirect bilirubin, downtrending haptoglobin. But the serum remained visually clear—no hemoglobinemia. Just a steady, smoldering hemolytic process consistent with warm autoimmune hemolytic anemia (WAIHA). Warm autoantibodies, as a reminder, are IgG antibodies directed against “self” antigens on red blood cells. They react best at 37°C—hence the name—and often appear as panagglutinins, reacting with all red cells regardless of antigen profile. While their specificity is typically undefined, they occasionally show preferential reactivity against Rh system antigens, especially RhD. But more often than not, the pattern is messy and nonspecific. What’s fascinating is that despite this overwhelming in vitro reactivity, patients with WAAs— even those with active hemolysis like mine —can often tolerate allogeneic transfusion just fine. That paradox is what makes WAAs so serologically intriguing and clinically humbling. The Practical Challenges of WAAs Rule Out Alloantibodies & Choose the Right Blood: The first priority is identifying any additional  alloantibodies that might be hiding beneath the autoantibody. This can require special techniques like autoadsorption or “saline AHG” testing that dampen WAA reactivity while preserving alloantibody detection. Once that’s done, most institutions provide ABO- and Rh-compatible units and match for Rh and Kell antigens the patient lacks to reduce future alloimmunization. There’s no universal standard for how far to take matching, but Rh/Kell coverage is a common and practical middle ground. Overlook the Incompatible Crossmatch—Sort Of: After all that, the crossmatch will almost always remain incompatible. And that’s okay. The phrase “least incompatible unit” gets tossed around a lot, but it’s not a guarantee of safety—just a shorthand for “we did our due diligence.” In truth, no serologic grading system has been validated to predict transfusion success in WAA cases. The unit that gives a 1+ reaction doesn’t necessarily survive better than one that’s 3+. What matters is clinical judgment and communication. Communicate Clearly with Clinicians: A DAT-positive patient, a fully incompatible crossmatch, and ongoing hemolysis can sound like a disaster to non-hematology clinicians. It’s our job to demystify that. I find myself saying this often: Yes, it looks scary on paper. But we’ve ruled out alloantibodies, chosen appropriate antigen-negative blood, and transfusion is still safe and appropriate when clinically indicated.  Avoid empty reassurances. Focus on shared decision-making. A Clinical Balancing Act WAAs can drive clinically significant hemolysis of the patient’s own red cells, and on occasion transfused donor cells. But not always, and paradoxically WAAs can sometimes spare donor cells while destroying native cells. That variability is part of what makes these antibodies so clinically fascinating. In vitro, they react with everything. In vivo, their effects exist on a spectrum—from silent bystanders to active participants in hemolysis. Managing WAAs is a constant balancing act. It requires knowing when to move forward despite serologic incompatibility, and when to stop and reassess. It demands vigilance, nuance, and collaboration. These antibodies force us to think beyond the test tube and remember that in transfusion medicine, the right answer is rarely just a result—it’s a decision.

When a patient refuses a blood transfusion, many clinicians feel backed into a corner. Sometimes, that refusal stems from deeply held religious beliefs—most notably among Jehovah’s Witnesses, who typically decline whole blood and its primary components. But here's the truth: refusing transfusion doesn’t mean refusing care. It means we need to be better stewards of everything else we have. 🔄 From “No” to “Now What?” Too often, the conversation stops at “They won’t accept blood.” But clinically, the more urgent question is: what can we offer instead? Fortunately, there’s a growing arsenal of strategies—many pioneered in response to transfusion refusal—that improve outcomes across the board. And the data backs that up. 💉 Bloodless Cardiac Surgery: The Data Consider cardiac surgery, one of the most transfusion-intensive fields in modern medicine. In a 10-year retrospective study of 91 Jehovah’s Witness patients undergoing cardiac procedures at a single institution, in-hospital mortality was just 5.5%, with outcomes for isolated coronary artery bypass grafting (CABG) and aortic valve replacement (AVR) falling within the 95% confidence intervals of Society of Thoracic Surgeons (STS) risk model predictions. Major complications—including reoperation, sepsis, stroke, and dialysis—remained low, and results were consistent across both elective and urgent surgeries.¹ These findings are echoed in a 2024 meta-analysis of 10 studies involving 780 Jehovah’s Witnesses and 1,182 non-Witness controls undergoing cardiac surgery. Despite 86% of non-Witness patients receiving at least one transfusion, there was no significant difference in perioperative mortality (OR 0.91; 95% CI, 0.55–1.52; p = 0.72). Jehovah’s Witnesses had less total blood loss (p = 0.001), and both pre- and postoperative hemoglobin levels were significantly higher.² In short: bloodless cardiac surgery is not only possible—it’s safe, when care is proactive and deliberate. 🧬 Blood Products and the Nuance of Refusal To care well for patients who decline transfusion, we need more than clinical tools—we need clarity. Here's the breakdown: Whole Blood Contains all components: red cells, white cells, plasma, and platelets. Jehovah’s Witnesses universally reject transfusion of whole blood. Primary Components Directly separated from whole blood. These are typically not accepted. Red blood cells Plasma Platelets White blood cells Secondary Components (Blood Derivatives) Created by further processing or fractionating blood components. Some Jehovah’s Witnesses accept these products, depending on individual beliefs and local congregation guidance. Albumin Immunoglobulins Coagulation factor concentrates Cryoprecipitate Autologous vs. Allogeneic Transfusion Allogeneic: from a donor—generally not accepted. Autologous: from the patient’s own circulation—may be accepted if done through a closed-loop system (e.g., cell salvage). This is why personalized planning and transparent communication are essential. Always clarify what the patient will or won’t accept—because individual preferences can vary dramatically within the community. 🛠️ What It Takes to Do Bloodless Medicine Well The best outcomes don’t come from avoiding transfusion—they come from deliberate patient blood management (PBM). Many of the tools that support JW patients improve care systemwide. Preoperative Optimization Iron, B12, and folate supplementation Erythropoiesis-stimulating agents Minimizing iatrogenic blood loss Intraoperative Precision TXA and other antifibrinolytics Meticulous surgical technique Cell salvage (when acceptable) Postoperative Support Tolerance of lower Hgb thresholds Oxygen and volume support Strategies to support marrow recovery 💡 What This Teaches Us Caring for patients who decline transfusion isn’t a constraint—it’s a clinical and ethical opportunity. It pushes us to: Communicate better Plan ahead Treat each patient as a partner in care And above all, it reminds us that the safest blood is the unit we never have to give. 📚 References Jassar AS, Makar M, Pullins E, et al. Cardiac Surgery in Jehovah’s Witness Patients: Ten-Year Experience. Ann Thorac Surg.  2012;93(1):19–25. doi:10.1016/j.athoracsur.2011.07.076 Gemelli M, Italiano EG, Geatti V, et al. Optimizing Safety and Success: The Advantages of Bloodless Cardiac Surgery. A Systematic Review and Meta-Analysis of Outcomes in Jehovah’s Witnesses. Curr Probl Cardiol.  2024;49(1, Part B):102078. doi: 10.1016/j.cpcardiol.2023.102078

I plugged in the numbers—height, weight, sex—and the algorithm spit out a total blood volume of 8 liters. Eight liters. That’s more than the average adult elephant. Okay, not really—but it was definitely more than was physiologically plausible for the patient in front of me. On paper, the formula worked. In practice, it made no sense. And that’s the quiet danger of laboratory standardization: the illusion of precision without the reality of accuracy. Algorithms, equations, and scoring systems are everywhere in lab medicine. We use them to estimate total blood volume, calculate corrected count increments, determine transfusion thresholds, risk-stratify patients, and more. They are essential. They are powerful. And they are, too often, blindly applied. Because we’ve come to equate “standardized” with “valid,” even when the standard was built on shaky ground. The Allure—and Illusion—of the Standard Standardization is the bedrock of laboratory medicine. It’s what lets us compare results across institutions, apply clinical guidelines, and run multicenter trials. Without it, evidence-based medicine would fall apart. But standardization is only as good as the data and assumptions it rests on. And in lab medicine, those assumptions are rarely neutral. When you dig into where these formulas come from—whether it’s Nadler’s formula for TBV, the use of sex-specific reference ranges, or scoring systems for conditions like heparin-induced thrombocytopenia or DIC—you often find something surprising: a very narrow foundation. Many of these tools were derived from datasets that are small, homogeneous, and unrepresentative of the patients we see today. And once a tool is canonized—once it makes it into the LIS, into the protocol, into the reference manual—it becomes difficult to question. But we should. Where Bias Hides in Plain Sight Bias in lab medicine isn’t always dramatic. Sometimes, it’s a small nudge—enough to make a test look slightly more normal than it should, or an algorithm overshoot the mark. But when scaled across thousands of patients, those nudges matter. 🧮 Biased Formulas Take total blood volume. Nadler’s formula is widely used and appears straightforward: plug in height, weight, and sex, and out comes a number. But Nadler’s equation was derived from a limited sample of healthy individuals in the 1960s—primarily white, young, and lean. Apply that formula to a patient with obesity or fluid retention, and you may end up drastically misestimating their TBV. That misestimation can lead to inappropriate collection during apheresis procedures. 📉 Reference Intervals We treat reference intervals as facts, but they’re often closer to educated guesses—highly dependent on the population used to derive them. Hemoglobin and creatinine reference ranges, for instance, are typically stratified by sex assigned at birth, but this binary stratification fails to reflect the diversity of physiologic reality. Patients on hormone therapy, those with chronic conditions, or those with differing muscle mass may fall outside “normal” ranges while being perfectly healthy—or may be misclassified because the ranges were never built with them in mind. Even more problematic, many intervals were never validated in pediatric, geriatric, or racially diverse populations. And yet these ranges shape everything: decisions to transfuse, to screen further, to diagnose. The reference range becomes the gatekeeper to clinical action—even when it shouldn't be. 📊 Risk Scores Scoring systems like the 4Ts for HIT or the ISTH DIC score assume access to certain labs, follow certain clinical patterns, and reward conformity. They can underperform in patients with atypical presentations or resource-limited settings. 🤖 Machine Learning and AI Even newer tools aren’t immune. Predictive models built from EHR data can reflect and amplify existing disparities—especially if the training data skews toward certain populations or omits key variables like socioeconomic status, language access, or prior healthcare usage. Bias doesn’t just live in the past—it gets encoded into the future. The Cost of “Close Enough” We love numbers in the lab. But “close enough” doesn’t cut it when you’re estimating blood volume for a patient with reduced muscle volume, or when a scoring tool steers you away from a diagnosis you should  be considering. Small inaccuracies in algorithms can lead to real-world consequences: missed diagnoses, under-treatment, over-transfusion, delayed care. And the worst part? These errors often go unrecognized—because the numbers looked clean, the boxes were checked, the equation was “standard.” Toward Better, Fairer Standardization So what do we do? We start by asking better questions: Who was this algorithm validated on? What assumptions does it make? Where does it fail? How does it perform in patients who don’t look like the “standard”? We need laboratory professionals involved not just in implementing tools, but in designing and validating them. We need to stop treating standardization as a destination and start treating it as a continuous process—one that requires transparency, adaptability, and humility. And most of all, we need to resist the seduction of certainty. Algorithms can guide us, but they can’t replace judgment. The Patient Didn't Have 8 Liters That patient didn’t have 8 liters of blood. But the algorithm said they did—and if we hadn’t caught it, we might have used that number to justify unsafe collection volumes. That’s the danger: when standardized tools are treated as facts, patients bear the consequences. Because in the end, the algorithm was wrong. And we knew better.

In lab medicine, we’re often asked to prove our worth with narrow metrics—cost per test, turnaround time, test volume. But these siloed measures rarely reflect the full impact of what we do. Over the past few years, I led two studies focused on a single test: the heparin-induced thrombocytopenia (HIT) antibody assay. Both began as practical projects to improve lab performance. But what they revealed went far beyond reagent costs or staffing efficiencies—they told a story about how laboratory decisions can fundamentally shape patient care. A Cost-Effective Innovation With Big Returns In the first study, published in Archives of Pathology & Laboratory Medicine , my team and I evaluated the cost-effectiveness and return on investment (ROI) of bringing the HIT antibody test in-house using the HemosIL platform. Like many institutions, we had been sending these tests out, with turnaround times of 2–4 days—delays that often led to empiric use of expensive heparin alternatives like argatroban. By implementing the assay on existing equipment, we reduced our average turnaround time to just over an hour. That change significantly cut down on unnecessary treatment. We found that the in-house test became cost-effective after as few as 8 tests, and at our institution’s volume, yielded an ROI of up to 298% annually. Fewer Days in the Hospital—But Only When the Test Is Negative The second study, published in American Journal of Clinical Pathology , took things further: Could this lab change improve measurable clinical outcomes? We focused on one critical metric—hospital length of stay (LOS)—and found that patients who had a negative HIT antibody result via in-house testing stayed 3.97 fewer days in the hospital, on average, compared to those with send-out testing. This wasn’t a systemwide trend. There was no decrease in acuity of the patients receiving the test or LOS for the institution as a whole. The reduction was specific to patients with negative test results—those who were able to safely avoid prolonged empiric treatment and be discharged sooner. It’s a clear example of how rapid, high-quality lab data can directly affect clinical decision-making and resource utilization. Moving Past Cost-Per-Test These projects changed how I think about lab value. The traditional cost-per-test model captures only a sliver of the story. It misses what really matters: avoiding harm, reducing overtreatment, shortening stays, saving money systemwide. These are outcomes that matter deeply to patients—and to healthcare systems under strain. To capture that value, we have to stop viewing labs as isolated cost centers and start recognizing them as engines of clinical efficiency. That means bringing lab leaders to the table in decisions about operations, informatics, and patient flow. It means designing metrics that reflect our role not just in diagnosis, but in care. A Path Forward I hope these studies offer a blueprint for others—not just for bringing HIT testing in-house, but for rethinking how we evaluate the success of laboratory innovations altogether. Because when we measure lab value only in terms of cost per test, we ignore everything that happens after the result is released. We ignore the treatment that’s avoided. The hospital days that are saved. The patient who gets discharged sooner, or doesn’t receive an unnecessary drug. We ignore the confidence we give clinicians to make the right call—and the cascading impact that confidence has across an entire health care system. Laboratory medicine isn’t just a line item on a budget. It’s an invisible backbone that supports nearly every clinical decision made in modern medicine. When we optimize the lab—not just for throughput, but for clinical integration—we create meaningful improvements in patient care, safety, and efficiency. That’s value. Not in theory, but in outcomes. It’s time we start telling that story—loudly, clearly, and with data to back it up. Raymond C, Dell’Osso L, Golding C, Zahner C. Cost-Effectiveness and Return on Investment Analysis of an In-house HemosIL Heparin-Induced Thrombocytopenia Antibody Assay at a Mid-Sized Institution.Archives of Pathology & Laboratory Medicine.  Published online 2023.📄 https://doi.org/10.5858/arpa.2023-0141-OA Raymond C, O’Rourke M, Dell’Osso L, Golding C, Zahner C. Analysis of Hospital Length of Stay and Cost Savings With an In-House Heparin-Induced Thrombocytopenia Antibody Assay at a Midsized Institution.American Journal of Clinical Pathology.  Published online 2023.📄 https://doi.org/10.1093/ajcp/aqad152

Pregnancy is a physiological feat—but when complications arise, the blood bank becomes a lifeline. Managing peripartum complications requires careful coordination between the clinical and transfusion teams. In this post, I’ll summarize the critical role of the blood bank in managing pregnancy-related complications, drawing from a recent presentation on this topic. 1. The Pregnant Patient’s Unique Physiology Pregnancy is characterized by profound hematologic and circulatory changes: Total blood volume increases by about 40%, but plasma volume increases by ~50%, leading to a dilutional (physiologic) anemia. Uterine blood flow increases from ~100 mL/min (non-pregnant) to ~700 mL/min at term. These changes optimize fetal perfusion—but they also create the potential for catastrophic hemorrhage. Any peripartum bleeding event occurs against the backdrop of this expanded yet vulnerable intravascular space. 2. Thrombocytopenia and Microangiopathy in Pregnancy: Distinguishing the Causes Pregnancy introduces unique diagnostic challenges when a patient presents with thrombocytopenia, hemolysis, and microangiopathic findings. While true thrombotic microangiopathies (TMAs) such as TTP and aHUS are rare, more common conditions like preeclampsia, HELLP syndrome, and acute fatty liver of pregnancy (AFLP) can present with overlapping laboratory abnormalities. Hypertensive Disorders of Pregnancy: Placental Dysfunction, Preeclampsia, and HELLP The pathophysiology of preeclampsia begins with abnormal placental development. Impaired trophoblastic invasion leads to defective remodeling of spiral arteries, resulting in placental ischemia. In response, the placenta releases antiangiogenic factors (like soluble fms-like tyrosine kinase-1, sFlt-1) into maternal circulation, triggering widespread endothelial dysfunction. This cascade manifests clinically as hypertension and end-organ injury—the hallmark of preeclampsia. While preeclampsia itself is not a thrombotic microangiopathy, the endothelial injury can cause thrombocytopenia, microangiopathic hemolysis, and elevated liver enzymes, mimicking features of TMA. HELLP syndrome represents a severe variant of preeclampsia, defined by hemolysis, elevated liver enzymes, and low platelets. Though it shares some features of TMA, its pathogenesis is rooted in placental dysfunction rather than primary thrombotic microvascular disease. Management of HELLP includes: Delivery of fetus and placenta (definitive treatment) Platelet thresholds: Vaginal delivery: ≥20,000/µL Cesarean delivery: ≥50,000/µL Hemoglobin target: >7 g/dL Coagulopathy: FFP support as needed Most cases of HELLP syndrome resolve within 72 hours postpartum following delivery of the fetus and placenta, which removes the underlying source of endothelial injury and inflammatory mediators. When ongoing thrombocytopenia, hemolysis, or organ dysfunction continues despite delivery and supportive care, therapeutic plasma exchange (TPE) may be initiated as a salvage therapy. While TPE is not routine first-line treatment for HELLP, emerging case series and observational studies suggest it may shorten disease course and reduce morbidity in refractory HELLP, particularly when initiated within 24 hours of delivery. TPE in this context is thought to remove circulating antiangiogenic factors (like soluble fms-like tyrosine kinase-1, sFlt-1) and other inflammatory mediators contributing to endothelial dysfunction. Additionally, it provides plasma replacement, which may help correct associated coagulopathies. Clinicians should have a low threshold for transfusion medicine consultation when HELLP does not follow the expected course of recovery, and the decision to initiate TPE should be individualized based on severity, lab trends, and potential overlap syndromes. True Thrombotic Microangiopathies: TTP and aHUS In contrast, thrombotic thrombocytopenic purpura (TTP) and atypical hemolytic uremic syndrome (aHUS) are true TMAs caused by ADAMTS13 deficiency and complement dysregulation, respectively. They require specific therapies (plasma exchange for TTP; complement inhibition for aHUS). Key differentiating features: Feature HELLP TTP aHUS Timing Late pregnancy/postpartum Any trimester/postpartum Any trimester/postpartum ADAMTS13 activity Normal/mildly low Severely low (<10%) Normal Creatinine Mild elevation Normal/slightly elevated Markedly elevated Platelets Low Very low Low Hemolysis Present Present Present Acute Fatty Liver of Pregnancy: The Great Mimicker AFLP is another critical diagnosis in the differential. Its pathophysiology involves hepatocellular microvesicular steatosis and apoptosis, leading to impaired hepatic function. While AFLP can mimic TMA with thrombocytopenia and coagulopathy, hemolysis is not a defining feature and is often absent. Key distinguishing findings favoring AFLP include: Profound hypoglycemia Elevated ammonia Prolonged PT/INR Low fibrinogen Hepatic encephalopathy Management of AFLP centers on prompt delivery and aggressive correction of coagulopathy with plasma, cryoprecipitate, and platelets to prevent bleeding. 3. Managing Massive Obstetric Hemorrhage: Obstetric MTP Obstetric hemorrhage is the leading cause of maternal mortality worldwide. Unlike trauma, obstetric massive transfusion protocols (MTP) must account for pregnancy-specific hemostatic challenges and the unique pathophysiology of peripartum bleeding. Common inciting events for obstetric MTP include: ✅ Placenta previa ✅ Placental abruption ✅ Uterine rupture ✅ Placenta accreta spectrum (accreta, increta, percreta) Management considerations: Recommended ratio: 1:1.5:1 (RBC:FFP:platelets) Early cryoprecipitate: Hypofibrinogenemia is common and correlates with poor outcomes; administer cryo in the first round if fibrinogen <200 mg/dL. Tranexamic acid (TXA): First-line therapy for postpartum hemorrhage per WOMAN trial. Antibody monitoring: While pregnant patients are not inherently at higher risk of alloantibody formation, any newly formed red cell antibodies following obstetric MTP pose a risk for hemolytic disease of the fetus and newborn (HDFN) in subsequent pregnancies. Therefore, meticulous post-transfusion follow-up with repeat antibody screening is critical to identify alloimmunization. 4. In Pregnancy, All Roads Lead to DIC A central truth of obstetric medicine is that almost every severe complication of pregnancy can induce disseminated intravascular coagulation (DIC). From preeclampsia to placental abruption, AFLP to sepsis, DIC is a common pathway of maternal decompensation. One of the most dramatic examples is amniotic fluid embolism (AFE). Amniotic Fluid Embolism: A Rare but Catastrophic Event AFE is a sudden, unpredictable complication resulting from entry of amniotic fluid into maternal circulation, triggering an anaphylactoid reaction. Risk factors include: ✅ Advanced maternal age ✅ Multiparity ✅ Rapid labor ✅ Cesarean delivery ✅ Instrumental delivery ✅ Placenta previa or accreta Clinically, AFE presents with acute hypoxia, hypotension, cardiovascular collapse, and DIC. Maternal mortality remains high despite optimal supportive care. Blood bank support during AFE focuses on: ✅ Massive transfusion with RBCs, FFP, platelets, and cryoprecipitate to correct consumptive coagulopathy ✅ Maintaining platelets ≥50,000/µL (cesarean) or ≥20,000/µL (vaginal) ✅ Rapid fibrinogen replacement to target fibrinogen >200 mg/dL ✅ Anticipating ongoing bleeding despite lab correction Key Takeaways for the Blood Bank Team ✅ Anticipate hemorrhagic risk in patients with placenta accreta spectrum, previa, abruption, or uterine rupture ✅ Tailor MTP for obstetrics: early cryoprecipitate and TXA are critical ✅ Differentiate causes of thrombocytopenia: preeclampsia/HELLP vs. TTP vs. aHUS dictates treatment ✅ Monitor for DIC in any critically ill pregnant patient ✅ Provide close antibody monitoring: alloantibodies may impact future pregnancies via HDFN even if not problematic in the index pregnancy Pregnancy is a state of delicate balance—and when that balance is lost, the blood bank’s interventions can mean the difference between life and death. Have you encountered these challenges in your practice? Share your experiences and insights below!

When we talk about blood transfusions, most people picture adults — trauma victims, surgical patients, the critically ill. But what about the smallest, most vulnerable patients: children and newborns? Pediatric and neonatal transfusion medicine is a field riddled with tough questions, thin evidence, and sometimes, uncomfortable extrapolations from adult data. Despite heroic efforts by clinicians and researchers, there remains a striking lack of robust, large-scale evidence to guide transfusion decisions in these populations. Why? Because no one wants to experiment on fragile babies. But without strong data, we’re often left making decisions in the dark. In this post, I’m summarizing two comprehensive reviews of current transfusion practices — one focused on pediatric patients 1 and one on neonates 2 — highlighting key studies, existing guidelines, and open questions in the field. These reviews help illuminate both where we’ve made progress and where major evidence gaps remain. Let’s break down what we know, where we’re guessing, and what the latest research is telling us. Pediatric Patients: Blood, Platelets, and Plasma For pediatric red blood cell (RBC) transfusions, guidelines like those from the AABB and TAXI (Pediatric Critical Care and Anemia Expertise Initiative) 3  recommend a restrictive approach — usually transfusing when hemoglobin drops below 7 g/dL in stable, non-cardiac intensive care patients. This approach stems largely from the TRIPICU study, 4  which showed no difference in outcomes (like mortality, infections, or multi-organ failure) between children transfused at 7 g/dL versus 9.5 g/dL. In fact, multiple analyses now suggest no clear benefit to “liberal” transfusion strategies. When it comes to pediatric platelets, things get trickier. Adult guidelines offer thresholds (e.g., 10,000/μL for prophylaxis, 50,000/μL for most surgeries), but evidence in children is sparse — and what we do have suggests that platelet count alone is a poor predictor of bleeding risk. The PLADO trial 5  found that lower platelet doses worked just as well to prevent bleeding, but importantly, children were at higher bleeding risk than adults, regardless of pre-transfusion count. This raises provocative questions: Do kids’ platelets behave differently? Do their vascular systems react in ways we don’t fully understand? For plasma transfusions, the story is sobering. Many plasma transfusions in both children and adults are given to “correct” lab abnormalities (like a high INR) before procedures when no bleeding is present — but randomized trials consistently show no benefit in such situations. It’s a potent reminder: abnormal numbers don’t always mean intervention is needed. Neonatal Patients: A World Apart Newborns, especially preemies, bring their own unique challenges. Neonatal red cell transfusion practices are influenced by the fascinating physiology of perinatal hematopoiesis. Term infants start with high hemoglobin levels (16–17 g/dL), but experience a “physiologic anemia” around 8 weeks as levels naturally drop before rising again. Premature infants, however, face even steeper drops due to shorter red cell lifespans and immature erythropoiesis. Two recent landmark trials, ETTNO 6  and TOP 7 , compared liberal and restrictive hematocrit thresholds for RBC transfusions in premature neonates. Both found no difference in survival or neurodevelopmental outcomes, supporting a move toward more restrictive strategies — though the nuances (like how early or prolonged anemia affects development) are still being debated. Platelet transfusion in neonates is another evolving area. Thrombocytopenia is common in preemies, but high thresholds (like 50,000/μL) may actually increase the risk of death and bleeding, as shown in the PlaNet-2 study. 8  A lower threshold of 25,000/μL appears safer, especially in the most fragile babies. In neonates, plasma transfusions are typically used for active bleeding, disseminated intravascular coagulation (DIC), severe liver disease, or as replacement fluid during procedures like ECMO or plasma exchange. While abnormal lab values (like elevated INR or aPTT) often trigger plasma use, studies show little benefit in correcting mild or moderate abnormalities in non-bleeding infants. This is partly because neonatal coagulation is naturally different: most clotting factors are around 50% of adult levels, but factors like fibrinogen, Factor V, Factor XIII, Factor VIII, and vWF are at or above adult levels at birth. Cryoprecipitate is mainly used to replace fibrinogen in cases of hypofibrinogenemia or dysfibrinogenemia, especially when bleeding or before surgery. Some centers are exploring human fibrinogen concentrate as an alternative, but thresholds for when to treat (often <100–150 mg/dL) remain debated. Importantly, routine prophylactic use of plasma or cryo in non-bleeding neonates is not well supported by evidence. What’s Next? If there’s a unifying theme across pediatric and neonatal transfusion medicine, it’s this: We need more and better evidence, and we need to stop reflexively applying adult rules to tiny bodies. Future research must tackle not just laboratory thresholds, but meaningful clinical outcomes — survival, development, quality of life. We also need smarter tools to assess bleeding risk beyond raw platelet counts or clotting times, especially in neonates whose physiology is fundamentally different. Until then, clinicians must walk a delicate line: applying the best available evidence, challenging outdated practices, and recognizing when “normalizing the numbers” may do more harm than good. Final Thoughts Pediatric and neonatal transfusion medicine asks us to confront some of the hardest questions in healthcare: How do we protect our most vulnerable patients without overreacting to imperfect data? How do we balance caution with evidence? And how do we, as stewards of limited and precious blood products, make sure we’re giving — or holding back — for the right reasons? In the end, perhaps the most powerful transfusion decision is the one not made lightly. Mo YD, Delaney M. Transfusion in Pediatric Patients. Clin Lab Med . 2021;41(1):1-14. doi:10.1016/j.cll.2020.10.001 Zerra PE, Josephson CD. Transfusion in Neonatal Patients. Clin Lab Med . 2021;41(1):15-34. doi:10.1016/j.cll.2020.10.002 Valentine SL, Bembea MM, Muszynski JA, et al. Consensus Recommendations for RBC Transfusion Practice in Critically Ill Children From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative. Pediatric Critical Care Medicine . 2018;19(9):884-898. doi:10.1097/PCC.0000000000001613 Lacroix J, Hébert PC, Hutchison JS, et al. Transfusion Strategies for Patients in Pediatric Intensive Care Units. New England Journal of Medicine . 2007;356(16):1609-1619. doi:10.1056/NEJMoa066240 Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of Prophylactic Platelet Transfusions and Prevention of Hemorrhage. New England Journal of Medicine . 2010;362(7):600-613. doi:10.1056/NEJMoa0904084 Franz AR, Engel C, Bassler D, et al. Effects of Liberal vs Restrictive Transfusion Thresholds on Survival and Neurocognitive Outcomes in Extremely Low-Birth-Weight Infants. JAMA . 2020;324(6):560. doi:10.1001/jama.2020.10690 Kirpalani H, Bell EF, Hintz SR, et al. Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants. New England Journal of Medicine . 2020;383(27):2639-2651. doi:10.1056/NEJMoa2020248 Curley A, Stanworth SJ, Willoughby K, et al. Randomized Trial of Platelet-Transfusion Thresholds in Neonates. New England Journal of Medicine . 2019;380(3):242-251. doi:10.1056/NEJMoa1807320